|
|
www.icpermed.eu
| twitter.com/icpermed |
|
|
Disclaimer for COVID-19 |
Due to the COVID-19 situation, ICPerMed and the
European Commission have been continuously in contact
since the emergency started. Please be informed that the
information in this newsletter is susceptible for
variation in the next months; all updates will be
provided in the news section on the ICPerMed website.
|
back to top
| | |
New Best Practice Examples are
online |
More and more successful approaches for personalised
medicine (PM) are coming up in recent years. To inform
about those, ICPerMed features Best Practice Examples on
the ICPerMed website. These are suggested by ICPerMed
members and discussed and approved by the ICPerMed
governance bodies according to pre-defined evaluation
criteria.
Two types of Best Practice Examples are being
featured on the ICPerMed website:
- Successful translation of PM research into an
added value for the patient. Besides medical research,
this type can also include examples with a strong
focus on the implementation of PM approaches,
including best practices on educational programmes,
inter-sectoral synergies and support tools for health
providers.
- Policy making and impact analysis for PM research.
Up to now ICPerMed approved and published 11 Best
Practice Examples, which are presented here.
Please find below teasers for the most recent Best
Practice Examples:
The “HAZLO” project: A personalised cardiac
rehabilitation programme. The objective of the
HAZLO (“Do it”) project is to implement and evaluate a
cardiac rehabilitation programme on low risk patients,
called e-supervision, that is optimised for the daily
life environment of the individual patient. The
acceptance and adherence of patients can be improved in
this way, while at the same time, the use of available
resources is optimised. Read
more
MedeA: Clinical Implementation of a
Pharmacogenetics Personalised Prescription System based
on e-health in a European Regional Health
Service
The MedeA (Medicina Personalizada Aplicada, Applied
Personalised Medicine) Initiative is a genuine
personalised medicine (PM) clinical implementation
programme. It is based on an analysis of each patient’s
individual pharmacogenetic biomarkers, drug-drug
interactions and clinical data evaluated in an e-health
strategy. This information is fed into a software system
called Personalized oriented Prescription System (PoPS).
It acts as a clinical decision support tool (CDST) for
the clinician and suggests the best drug or drug
combination and dose for the individual patient. Read
more
|
back to top
| | |
Presentation of ICPerMed and the
ICPerMed Family through a series of videos |
A series of six promotional videos presenting the
ICPerMed ecosystem, the aims and activities supporting
the realisation of personalised medicine has been
published on the ICPerMed YouTube channel and the
ICPerMed website. These videos aim to promote ICPerMed
and the ICPerMed Family, to disseminate ICPerMed vision
and actions and to generate interest and engagement from
new partners or stakeholders.
A first video is designated to ICPerMed, its role in
developing personalised medicine (PM) strategies to
align research and funding activities on European and
international level, in fostering actions toward PM
implementation by bringing together key stakeholders,
stimulating exchanges and collaborations, and in
promoting good practices. Watch
on YouTube
Through interviews of Irene Norstedt (European
Commission), Ejner Moltzen (ICPerMed) and Wolfgang
Ballensiefen (ICPerMed), a second video takes us back on
the origin of ICPerMed, the progress made until now and
provides some outlook for the future of PM. Watch
on YouTube
Finally, four additional videos focus on the ICPerMed
Family and their support to make PM a reality. These
videos show close collaborations of ICPerMed with the
European Research Area Network for Personalised Medicine
(ERA PerMed) and several Coordination and Support
Actions (CSAs) funded by the European Commission:
- A video dedicated to ERA PerMed
highlights how the development of PM is fostered
through research project funding reflecting ICPerMed’s
strategic vision.
Watch
on YouTube
- A video advocating the role of SAPHIRe
and Regions4PerMed
emphasises the importance of regions for PM
development and implementation and demonstrates how we
can learn from regional experiences to further
scale-up PM approaches.
Watch
on YouTube
- Through the presentation of EULAC-PerMed,
Sino-EU PerMed, IC2PerMed and
EU-Africa PerMed, a video highlights
the need for international collaboration to ensure
that PM approaches are applicable as broadly as
possible and not limited to a specific regional
context, to make healthcare more efficient and
equitable.
Watch
on YouTube
- Last but not least, PERMIT and
HEcoPerMed representatives present
the clinical perspective in PM and explain the
importance of health economic modelling and payment
strategies for PM implementation.
Watch
on YouTube |
back to top
| | |
“ICPerMed Family Meeting – Joining
Forces” (internal meeting) on 9-10 November 2021
|
The “ICPerMed Family Meeting – Joining
Forces” will take place virtually on 9-10
November 2021 as a by-invitation-only event. This first
“ICPerMed Family meeting” aims to explore cooperation
and synergies of ICPerMed and ICPerMed-related CSAs (a
set of projects funded by the European Commission in
different areas of personalised medicine (PM) in support
of ICPerMed) as well as ERA PerMed and possibly other
related projects. The interactive sessions will deal
with specific topics from the fields of Research &
Technology, Health Systems, Education and Literacy,
Regions and Internationalisation.
Besides establishing a forum for discussion, the aim
of the family meeting is to harmonise future activities,
to expand cooperation and to jointly develop strategies
for fostering PM research and implementation of PM
approaches in healthcare and health systems.
|
back to top
| | |
Save-the-date: ICPerMed Training Event
“Personalised Medicine Research: Key issues” |
ICPerMed is happy to inform you about the upcoming
1st “ICPerMed Training – Personalised Medicine Research:
Key issues” on 1-2 December 2021. The target group of
the training is actors worldwide at the very beginning
of their careers. About 40 applicants will be selected
to participate in the free-of-charge training in English
as training language. Details on how to apply will be
published on the ICPerMed website beginning of October
2021.
The importance of personalised medicine (PM) to cure
the human being is becoming evident. This training will
enable participants to improve the personal perspective
and convey the fundaments to understand the complexity
of PM for the establishment of new research settings.
The focus of this training will be around PM research
projects and will tackle ethical, legal, social and
genetic aspects.
Together with experts in PM, definitions, policies
and guidelines will be presented, while practical
examples will give the opportunity for all participants
to actively engage with the most relevant issues. In
this two-day training, participants will gain knowledge
in key aspects of PM research, gain new skills and
develop synergies.
This online training is one of several activities of
ICPerMed in order to support research and implementation
of PM in Europe and beyond. |
back to top
| | |
Pre-Announcement: “Best Practice
in Personalised Medicine” Recognition 2021 |
ICPerMed is pleased to inform you that its fourth
“Best Practice in Personalised Medicine” Recognition
will open for applications on 15 November 2021.
The objective of this Recognition is to honour,
encourage, promote and disseminate outstanding
evidence-based applications in the field of personalised
medicine (PM), focusing on the implementation of PM
research. The Recognition is open to candidates
worldwide, who have published scientific papers (paper
accepted by the respective editor) and/or developed best
practice strategies (training programmes or
interdisciplinary/intersectoral groups of collaboration)
for implementation of PM approaches between 1 November
2019 and 31 December 2020. The deadline for proposal
submission will presumably be 29 January 2022.
Applications concerning an ongoing or recently
accomplished training or collaboration need to be
accompanied by a supporting documentation.
The submission including the documents to be
evaluated (single-stage evaluation) will only be
accepted in English and only one submission per
applicant is possible.
In 2022, those applications addressing outstanding PM
outcomes will be announced as winners and will be
invited to present their approaches during the next
ICPerMed Event. The winners will be honoured by a 500 €
non-cash value support for dissemination.
More information on the ICPerMed “Best Practice in
Personalised Medicine” Recognition 2021 will soon be
available on the ICPerMed webpage. |
back to top
| | |
Update on preparations of the European
Partnership for Personalised Medicine (EP PerMed) under
Horizon Europe |
The virtual Information Event "European Partnership
for Personalised Medicine (EP PerMed) calling for
national and regional involvement" organised by ICPerMed
and ERA PerMed took place on 31 May 2021. With over 200
participants from 22 different countries, the interest
in discussing the opportunities and perspectives of the
EP PerMed was very high.
The aim of this event was to inform about the joint
proposal of ICPerMed and ERA PerMed for the EP PerMed,
its objectives, activities and expected impacts, the
overall framework for engagement in this partnership and
its international dimension. Further ICPerMed and ERA
PerMed wanted to engage with national and regional
authorities as well as funders and stakeholders
interested in promoting and implementing personalised
medicine PM approaches in their countries and regions,
with the overall aim to foster personalised diagnostics,
therapies and prevention for the benefit of patients and
citizens. Besides the EP
PerMed draft concept paper and the EP
PerMed Guide, key aspects of the EP PerMed such as
the target groups, the involvement of regions, industry
and international partners as well as joint funding
opportunities and the establishment of national hubs
have been introduced and are available in form of
Information Sheets.
The information given aimed to support actors on the
regional and national level to start preparations for
the partnership, e.g. to mobilise the national budget
commitments and receive stakeholder input for the
creation of the partnership.
The presented content was the result of ICPerMed/ERA
PerMed reflections on EP PerMed aspects. The concept,
legal and financial frameworks for the partnership are
still under development and the EP PerMed Guide and
Information Sheets will be adapted in the future to
update such technical aspects when relevant. All
documents received valuable input from the European
Commission but do not represent official documents of
the European Commission.
The presentations
and video recordings of the event are now
available for download on the new EP
PerMed subpage.
Next step in the partnership preparation will be the
first member states consultation meeting for the EP
PerMed organised by the European Commission on 28
September 2021.
Contact details ICPerMed/ERA PerMed
preparatory group:
|
back to top
| | |
Update on ERA PerMed |
The ongoing ERA PerMed fourth Joint Transnational
Call (JTC2021) for research projects in personalised
medicine (PM) on the topic “Multidisciplinary research
projects on Personalised Medicine: Development of
clinical support tools for personalised medicine
implementation” is supported by 30 funding organisations
from 23 countries. This call was launched in December
2020 with the Italian Ministry of Health (It-MoH) as
Joint Call Secretariat and was of great interest within
the research community. 204 eligible pre-proposals,
comprising of 984 research groups, were submitted under
the JTC2021, out of which 59 were invited to submit a
full-proposal. The full-proposal final evaluation took
place virtually this month and the final funding
decision is expected soon.
With this call (non-cofunded by the EC), ERA PerMed
fosters research and innovation activities that build
close linkages between clinical research, computer
science/medical informatics and research on ethical,
legal and social aspects (ELSA) in the field of PM. The
overarching goal is to improve disease prevention and
disease management, based on broader and more
efficiently characterised and defined patient
stratification, diagnostics and tailored
treatment/prevention protocols for both patients and
individuals at risk of disease.
The JTC2021 is constructed around the following three
research areas in order to ensure the development of
specific PM approaches, taking into account the major
aspects for their successful implementation in the
health systems: (1) “Translating Basic to Clinical
Research and Beyond”, (2) “Data and Information and
Communication Technology (ICT)” and (3) “Research
towards Responsible Implementation in Healthcare”.
For the coming year, ERA PerMed has decided to launch
a fifth, initially not foreseen, joint call for
proposals (JTC2022), made possible thanks to a one-year
no-cost prolongation accorded to ERA PerMed by the
European Commission. The call will be jointly
coordinated by the Spanish National Institute of Health
Carlos III (ISCIII) and the French National Research
Agency (ANR) and is expected to be pre-announced in
November 2021.
For further information about ERA PerMed calls,
please refer to the ERA PerMed
website. |
back to top
| | |
|
PERMIT: PERsonalised
Medicine Trials - Update
Over the course of the past six months the PERMIT
project successfully held over ten online working
sessions, focus groups and workshops to discuss the gaps
in personalised medicine research methodologies. These
gaps were identified through a series of scoping reviews
(results currently under review for publication) during
the project’s first year. Consortium members have
gathered with field experts and regulators to analyse
and discuss the gaps with the aim of jointly defining
recommendations and identifying opportunities for
standardisation. The project will now organise a final
series of workshops where drafts of the recommendations
will be presented and discussed with consortium members
and field experts, including all key stakeholders. The
recommendations will then be made publicly available,
and dedicated training material will be developed to
facilitate the adoption and implementation of the
recommendations. More details on the different meetings
that took place can be found on the PERMIT
website.
IC2PerMed: New
publication
In August 2021, IC2PerMed published its first
contribution in Public Health Genomics (Karger) entitled
“Integrating China in the International Consortium for
Personalised Medicine: The Coordination and Support
Action to Foster Collaboration in Personalised Medicine
Development between Europe and China”. In this article,
the background and the overall objectives of IC2PerMed
are thoroughly described alongside with the activities
of the three working groups and the extensive
involvement of experts that have been carried out during
the first part of the project.
The international collaboration between Europe and
China in the field of personalised medicine is intended
to cooperate for global challenges and support several
joint projects between European and Chinese
universities, research institutes and companies. Thus,
given the strong interest from both Europe and China in
advancing personalised medicine approaches, the
resilient and sustainable cross-border collaboration
raised from this project can build effective leverage to
accelerate the effective translation of such innovation
into health systems, advance research, and ensure that
such change follows directions towards the path of
sustainability.
Reference: Morsella A, Cadeddu C, Castagna C,
Hoxhaj I, Sassano M, Wang CM, Wang L, Klessova S, de
Belvis AG, Boccia S, Ricciardi W. "Integrating China in
the International Consortium for Personalized Medicine":
The Coordination and Support Action to Foster
Collaboration in Personalized Medicine Development
between Europe and China. Public Health Genomics. 2021
Aug 13:1-5. doi:
10.1159/000516264. Epub ahead of print. PMID:
34392247.
EULAC PerMed: Webinar
series
EULAC
PerMed is not letting the pandemic put its
activities on hold, and continues with the webinar
series. On 21 May 2021, a webinar on Systems
biology and Personalised Medicine was held. Dr.
Bruno Bezerril Andrade from Fiocruz in Brazil and Dr.
Martin Hoffman-Apitius from the Fraunhofer Institute for
Algorithms and Scientific Computing (SCAI) in Germany
shared information on their ongoing work, where systems
biology methods are applied in two different fields for
a personalised approach.
In July 2021, the webinar on Opportunities
in Personalized Medicine for non-European countries
presented by Mr. Bruno Mourenza from APRE in
collaboration with the Italian Ministry of Health was an
excellent instrument to introduce the existing funding
opportunities in PM within the European Research and
Innovation Programme, Horizon Europe.
This and more can be found in the project’s latest
newsletter to which you can subscribe here.
|
back to top
| | |
Facts: |
- ICPerMed started in November 2016
- 48 funding organisations and ministries
- 29 countries
- 5 Working Groups: Clinical Studies in Personalised
Medicine, Personalised Medicine in healthcare, Patients’
empowerment, Education & Curricula in Personalised
Medicine, and Health economic value of Personalised
Medicine
ICPerMed is also represented on Twitter. Follow us! @ICPerMed | |
| |